Nautilus Biotechnolgy (NAUT) AI Stock Analysis

• Market Cap: $94.74M
• Dividend Yield: N/A
• Average Volume (3M): 155.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: N/A
• EPS Growth: -10.58%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.56
• Shares Outstanding: 126,148,470
• 10 Day Avg. Volume: 179,012
• 30 Day Avg. Volume: 155,209
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -2.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.75
• Price Target Upside: 208.99% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

The overall score is weighed down by the company's lack of revenue and significant financial losses. While there are positive scientific advancements and a strong cash position, the delayed product launch and current bearish technical indicators reflect challenges in the near term.

Positive Factors

Cash Management

Prudent cost management enables cash runway to extend into 2027.

Product Development

Management expressed a high degree of confidence in being on a path to a full commercial launch of their PriSM technology for broadscale discovery.

Technology Confidence

Management remains optimistic about their technology and commercial opportunity, with strong customer interest.

Negative Factors

Internal Milestones

The company was behind on internal milestones with respect to a major broadscale goal of quantifying a significant number of proteins from a complex sample.

Launch Delays

Commercial launch now expected in late-2026, delayed from late 2025, due to modifications needed on the assay configuration and surface chemistry.

Stock Performance

NAUT traded down nearly (20%) after another commercial launch timeline delay, this one a push out to late 2026.

Nautilus Biotechnolgy Business Overview & Revenue Model

Company Description

Nautilus Biotechnology (NAUT) is a pioneering company in the biotechnology sector, focused on revolutionizing the field of proteomics. The company's core product is its proprietary platform designed to comprehensively analyze and quantify proteins with unprecedented sensitivity and scale. This breakthrough technology aims to accelerate biomedical research and development, enabling deeper insights into the proteome that can drive advancements in drug discovery, diagnostics, and personalized medicine.

How the Company Makes Money

Nautilus Biotechnology generates revenue primarily through the commercialization of its proteomics platform. The company offers its technology to pharmaceutical companies, academic institutions, and research organizations, which use it to conduct detailed protein analysis. Key revenue streams include the sale of instruments, consumables, and related services required to operate the platform. Additionally, Nautilus may engage in strategic partnerships and collaborations with other entities in the biotech and pharmaceutical industries, which can provide further revenue through joint research projects, licensing agreements, and milestone payments based on the successful achievement of specific research or development goals.

Nautilus Biotechnolgy Financial Statement Overview

Summary

Nautilus Biotechnology is in an early growth phase typical of biotech firms, with no revenue and significant operational losses. Despite strong cash reserves and low leverage providing some financial stability, sustained losses and significant cash outflow highlight the challenges in achieving profitability.

Income Statement

Nautilus Biotechnology has consistently reported zero revenue, reflecting its early-stage development status typical for biotech firms. The company faces significant net losses, with a negative net profit margin and no gross profit. Revenue growth is non-existent, while operating expenses remain high, adversely affecting EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a relatively strong equity position with a consistent decrease in stockholders' equity over recent years, reflecting ongoing losses. The debt-to-equity ratio is favorable, indicating low leverage, but the negative equity in earlier years signals financial instability. The equity ratio is reasonably high, suggesting a good proportion of assets financed by equity.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, reflecting high cash burn typical for biotech startups. The free cash flow to net income ratio is negative, indicating cash outflows exceed inflows. However, substantial cash reserves provide a buffer against short-term financial challenges.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-5.71M	-3.42M	-2.84M	-2.35M
	EBIT
0.00	-76.15M	-63.62M	-50.50M	-15.74M
	EBITDA
0.00	-74.30M	-54.51M	-47.47M	-13.27M
	Net Income Common Stockholders
-70.78M	-63.67M	-63.74M	-50.31M	-15.62M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
129.89M	173.42M	184.47M	345.73M	76.74M
	Total Assets
242.74M	305.56M	350.05M	398.45M	85.01M
	Total Debt
30.48M	34.63M	30.33M	30.03M	4.78M
	Net Debt
2.83M	15.23M	-84.19M	-155.59M	-31.83M
	Total Liabilities
34.01M	40.21M	35.13M	34.87M	114.73M
	Stockholders Equity
208.73M	265.35M	314.92M	363.58M	-29.72M
Cash Flow		Free Cash Flow
-61.27M	-54.15M	-48.13M	-41.51M	-14.92M
	Operating Cash Flow
-59.15M	-51.71M	-45.81M	-39.24M	-14.00M
	Investing Cash Flow
66.25M	-43.73M	-25.74M	-138.96M	-25.28M
	Financing Cash Flow
1.14M	368.00K	562.00K	327.45M	75.90M

Nautilus Biotechnolgy Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.89
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Negative. The current price of 0.89 is below the 20-day moving average (MA) of 0.99, below the 50-day MA of 1.35, and below the 200-day MA of 2.16, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 25.83 is Positive, neither overbought nor oversold. The STOCH value of 6.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAUT.

Nautilus Biotechnolgy Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	66 Neutral	$8.72B	108.67	2.27%	―	0.66%	-75.89%
ILMN	49 Neutral	$12.10B	―	-30.11%	―	-2.93%	-4.69%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
DNA	48 Neutral	$328.47M	―	-60.34%	―	-9.71%	42.17%
PACB	45 Neutral	$336.57M	―	-51.11%	―	-23.19%	6.27%
TWST	44 Neutral	$2.24B	―	-37.73%	―	25.85%	6.06%
NAUT	30 Underperform	$94.74M	―	-29.86%	―	―	-10.58%

Nautilus Biotechnolgy Corporate Events

Nautilus Biotechnology Announces Board Changes for 2025

Nautilus Biotechnology announced changes in its board of directors for the 2025 annual meeting, with Vijay Pande and Michael Altman stepping down, and Matthew McIlwain transitioning to a Class I director to maintain board balance. The company also reported its financial results for the fourth quarter and fiscal year 2024, highlighting a slight increase in operating expenses and a net loss compared to the previous year. Nautilus plans to launch its proteome analysis platform in late 2026 and has reduced its workforce by 16% to align resources with development goals, aiming to extend its cash runway through 2027.

Nautilus Biotechnology Announces Board Member Departures

On January 27 and 28, 2025, Vijay Pande and Michael Altman informed Nautilus Biotechnology that they will not stand for re-election to the board of directors at the 2025 annual meeting. Their decision is not due to any disagreements with the company’s operations, policies, or practices, indicating stability and alignment in the company’s strategic direction.